Retatrutide (Reta)

5mg

$45.00

Specification 5mg 10mg 15mg 20mg 30mg 60mg

Retatrutide is an experimental triple-hormone receptor agonist (GLP-1, GIP, and Glucagon) designed for obesity and diabetes, showing promising phase 2 trial results for significant weight loss. It is currently in phase 3 trials (e.g., NCT04881760) with potential FDA approval expected around 2027. Common side effects include nausea, diarrhea, vomiting, and constipation.

How it Works (Triple Action)
Retatrutide, also known as LY3437943, works by activating three receptors—glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG).

Appetite Control: Like GLP-1s, it reduces hunger.
Metabolic Boost: The addition of the glucagon receptor agonist is thought to help increase energy expenditure.

Weight Loss Efficacy: Phase 2 studies showed substantial weight reduction, with higher doses (up to 12 mg) showing greater efficacy over 48 weeks.

Potential Benefits

Significant Weight Loss: Trials have demonstrated potential for profound weight reduction in patients with obesity or overweight, with some individuals losing a significant percentage of their body weight.
Improved Metabolic Function: Beyond weight loss, it targets improved insulin sensitivity.
Potential Other Indications: Research is exploring its use for obstructive sleep apnea and knee osteoarthritis.